Median patient age was 8.5 years, with 107 patients older than 18 years; 656 patients were male and 431 were female. Demographic details and clinical parameters were analyzed at presentation and at last visit. With 41 recorded deaths, actuarial survival at 26.9 years was 50%, and under-5 ...
If untreated, typically results in death in the first year of life, due to infection or cardiovascular complications. α-Thalassemia • When 1 of the 2 α-genes are mutated, no disease is present. • When 2 genes are mutated (α-thalassemia trait), a patient has mild anemia of no cl...
patient satisfac- tion, and quality of life.56 The possibility that cardiac siderosis and amlodipine com- bined with chelation therapy reduces cardiac iron more effectively than chelation therapy alone is currently under investigation.57 Chelation dosing and regimens require adjustments for changing circum...
As life expectancy for β-thalassemia patients extends, the use of neurophysiologic and neuropsychologic monitoring becomes imperative, enabling early detection of neural pathway impairment and allowing for appropriate management, in order to achieve a better life quality for this patient group. 展开 ...
The patient's environmental and socio- economic status, is a major determinant of life span and the occurrence of systemic symptoms [7]. There- fore, variety of the symptoms may be attributed to differences by regions. The course of the disease in patients with TM, subjecte...
A case of bilateral paravertebral extramedullary hematopoietic masses with symptomatic pleural effusion in a patient with β-thalassemia intermedia is repo... A Taher,H Skouri,W Jaber,... - 《Hemoglobin》 被引量: 14发表: 2001年 加载更多来源...
(RDW), and the patient’s history can exclude some o these etiologies. The MCV is usually less than 75 f with thalassemia and rarely less than 80 f in iron de ciency until the hematocrit is less than 30 percent. For children, the Mentzer index (MCV/red blood cell count) can ...
Thalassemia and CHAPTERsickle cell disease 17Irene AG Roberts and Josu de la Fuente Introduction Advances in supportive care for patients with thalassemia and sickle cell disease have dramatically improved life expectancy. Nevertheless, patients continue to suffer disabling symptoms, particularly during ...
In some cases the cause of anemia is evident, e.g., a patient with a known history of sickle cell disease or thalassemia, GI bleeding, or surgical blood loss. When the cause is not obvious, a systematic diagnostic approach often leads to the correct diagnosis. The hallmarks of such an ...
First, for the sake of patient understanding, this study concretized the concept of sustaining life with blood transfusion. However, in reality, the costs of temporarily alleviating their anemia status also included the costs of testing, iron chelation, etc. Blood was only the most crucial ...